World's Best Scientists 2026 revealed!
Olli Silvennoinen

Olli Silvennoinen

D-Index & Metrics

Molecular Biology

D-Index
63
Citations
19893
World Ranking
1781
National Ranking
7

Olli Silvennoinen publication distribution in Molecular Biology in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Molecular Biology in 2026. The highlighted bar marks where Olli Silvennoinen sits on this spectrum.

47–56 publications: 7 scientists 57–66 publications: 17 scientists 67–76 publications: 65 scientists 77–86 publications: 90 scientists 87–96 publications: 125 scientists 97–106 publications: 131 scientists 107–116 publications: 162 scientists 117–126 publications: 177 scientists 127–136 publications: 158 scientists 137–146 publications: 158 scientists 147–156 publications: 146 scientists 157–166 publications: 159 scientists 167–176 publications: 131 scientists 177–186 publications: 110 scientists 187–196 publications: 112 scientists 197–206 publications: 100 scientists 207–216 publications: 89 scientists 217–226 publications: 98 scientists 227–236 publications: 74 scientists 237–246 publications: 72 scientists 247–256 publications: 63 scientists 257–266 publications: 53 scientists 267–276 publications: 54 scientists 277–286 publications: 49 scientists 287–296 publications: 52 scientists 297–306 publications: 43 scientists 307–316 publications: 46 scientists 317–326 publications: 41 scientists 327–336 publications: 42 scientists 337–346 publications: 31 scientists 347–356 publications: 28 scientists 357–366 publications: 29 scientists 367–376 publications: 26 scientists 377–386 publications: 24 scientists 387–396 publications: 24 scientists 397–406 publications: 14 scientists 407–416 publications: 13 scientists 417–426 publications: 20 scientists 427–436 publications: 12 scientists 437–446 publications: 20 scientists 447–456 publications: 11 scientists 457–466 publications: 10 scientists 467–476 publications: 14 scientists 477–486 publications: 14 scientists 487–496 publications: 10 scientists 497–506 publications: 13 scientists 507–516 publications: 13 scientists 517–526 publications: 2 scientists 527–536 publications: 4 scientists 537–546 publications: 6 scientists 547–556 publications: 8 scientists 557–563 publications: 6 scientists 564+ publications: 100 scientists
47 publications 564+

This scientist: 130 publications — 27th percentile

27% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 564 publications or more.

Olli Silvennoinen D-index placement in Molecular Biology in 2026

The chart shows the D-index (discipline H-index) distribution of Molecular Biology scientists ranked by Research.com in 2026. The highlighted bar marks where Olli Silvennoinen sits on this spectrum.

40–41 D-Index: 36 scientists 42–43 D-Index: 101 scientists 44–45 D-Index: 115 scientists 46–47 D-Index: 121 scientists 48–49 D-Index: 118 scientists 50–51 D-Index: 130 scientists 52–53 D-Index: 106 scientists 54–55 D-Index: 116 scientists 56–57 D-Index: 113 scientists 58–59 D-Index: 129 scientists 60–61 D-Index: 120 scientists 62–63 D-Index: 105 scientists 64–65 D-Index: 131 scientists 66–67 D-Index: 95 scientists 68–69 D-Index: 97 scientists 70–71 D-Index: 106 scientists 72–73 D-Index: 83 scientists 74–75 D-Index: 89 scientists 76–77 D-Index: 77 scientists 78–79 D-Index: 70 scientists 80–81 D-Index: 73 scientists 82–83 D-Index: 60 scientists 84–85 D-Index: 48 scientists 86–87 D-Index: 45 scientists 88–89 D-Index: 50 scientists 90–91 D-Index: 31 scientists 92–93 D-Index: 51 scientists 94–95 D-Index: 43 scientists 96–97 D-Index: 38 scientists 98–99 D-Index: 39 scientists 100–101 D-Index: 41 scientists 102–103 D-Index: 29 scientists 104–105 D-Index: 33 scientists 106–107 D-Index: 35 scientists 108–109 D-Index: 20 scientists 110–111 D-Index: 38 scientists 112–113 D-Index: 19 scientists 114–115 D-Index: 28 scientists 116–117 D-Index: 13 scientists 118–119 D-Index: 23 scientists 120–121 D-Index: 16 scientists 122–123 D-Index: 15 scientists 124–125 D-Index: 11 scientists 126–127 D-Index: 21 scientists 128–129 D-Index: 7 scientists 130–131 D-Index: 13 scientists 132–133 D-Index: 14 scientists 134–135 D-Index: 17 scientists 136–137 D-Index: 9 scientists 138–139 D-Index: 8 scientists 140–141 D-Index: 16 scientists 142–143 D-Index: 7 scientists 144 D-Index: 7 scientists 145+ D-Index: 100 scientists
40 D-Index 145+

This scientist: 63 D-Index — 43rd percentile

43% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 145 D-Index or more.

Overview

Olli Silvennoinen is affiliated with Tampere University in Finland and has contributed extensively to the field of medicine, with a particular focus on genetics, oncology, rheumatology, hematology, and molecular biology. Their research primarily addresses cytokine signaling pathways, myeloproliferative neoplasms, and rheumatoid arthritis, among other topics.

Their work includes investigations into rheumatoid arthritis therapies, acute myeloid leukemia, systemic lupus erythematosus, chronic myeloid leukemia treatments, and eosinophilic disorders and syndromes.

Frequent coauthors in Silvennoinen's research include Anniina Virtanen, T. Haikarainen, Pia Isomäki, Maaria Palmroth, and Ritva Peltomaa.

Olli Silvennoinen has published several papers, including the following:

  • Tofacitinib Suppresses Several JAK-STAT Pathways in Rheumatoid Arthritis In Vivo and Baseline Signaling Profile Associates With Treatment Response, 2021, Frontiers in Immunology
  • JAK inhibitor selectivity: new opportunities, better drugs?, 2024, Nature Reviews Rheumatology
  • Janus Kinases in Leukemia, 2021, Cancers
  • Tofacitinib treatment modulates the levels of several inflammation-related plasma proteins in rheumatoid arthritis and baseline levels of soluble biomarkers associate with the treatment response, 2022, Clinical & Experimental Immunology
  • Differences in JAK Isoform Selectivity Among Different Types of JAK Inhibitors Evaluated for Rheumatic Diseases Through In Vitro Profiling, 2023, Arthritis & Rheumatology

Their research is frequently published in journals such as Frontiers in Immunology, Cancers, Pharmaceuticals, Science Advances, and FASEB BioAdvances.

Best Publications

  • JAK2 associates with the erythropoietin receptor and is tyrosine phosphorylated and activated following stimulation with erythropoietin

    Bruce A. Witthuhn;Frederick W. Quelle;Olli Silvennoinen;Taolin Yi

  • Identification of JAK2 as a growth hormone receptor-associated tyrosine kinase

    Lawrence S. Argetsinger;George S. Campbell;Xianjie Yang;Bruce A. Witthuhn

  • Association and activation of Jak-Tyk kinases by CNTF-LIF-OSM-IL-6 beta receptor components.

    Neil Stahl;Teri G. Boulton;Thomas Farruggella;Nancy Y. Ip

  • The protein tyrosine kinase JAK1 complements defects in interferon-α/β and -γ signal transduction

    Mathias Müller;James Briscoe;Carl Laxton;Dmitry Guschin

  • Signaling by the cytokine receptor superfamily: JAKs and STATs

    James N. Ihle;Bruce A. Witthuhn;Frederick W. Quelle;Koh Yamamoto

  • SIGNALING THROUGH THE HEMATOPOIETIC CYTOKINE RECEPTORS

    James N. Ihle;Bruce A. Witthuhn;Frederick W. Quelle;Koh Yamamoto

  • Involvement of the Jak-3 Janus kinase in signalling by interleukins 2 and 4 in lymphoid and myeloid cells

    Bruce A. Witthuhn;Olli Silvennoinen;Osamu Miura;Osamu Miura;Koon Siew Lai

  • The Janus kinases (Jaks)

    Kunihiro Yamaoka;Pipsa Saharinen;Marko Pesu;Vance E.T. Holt

  • Regulation of the Jak2 Tyrosine Kinase by Its Pseudokinase Domain

    Pipsa Saharinen;Kati Takaluoma;Olli Silvennoinen;Olli Silvennoinen

  • Interferon-induced nuclear signalling by Jak protein tyrosine kinases

    Olli Silvennoinen;James N. Ihle;Joseph Schlessinger;David E. Levy

  • The pseudokinase domain is required for suppression of basal activity of Jak2 and Jak3 tyrosine kinases and for cytokine-inducible activation of signal transduction.

    Pipsa Saharinen;Olli Silvennoinen;Olli Silvennoinen

  • Activation of JAK2 kinase mediated by the interleukin 6 signal transducer gp130.

    Masashi Narazaki;Bruce A. Witthuhn;Kanji Yoshida;Olli Silvennoinen

  • Model for long QT syndrome type 2 using human iPS cells demonstrates arrhythmogenic characteristics in cell culture.

    Anna L. Lahti;Ville J. Kujala;Hugh Chapman;Ari-Pekka Koivisto

  • Regulation of Jak2 through the Ubiquitin-Proteasome Pathway Involves Phosphorylation of Jak2 on Y1007 and Interaction with SOCS-1

    Daniela Ungureanu;Pipsa Saharinen;Ilkka Junttila;Douglas J. Hilton

  • The Pseudokinase Domain of JAK2 Is a Dual-Specificity Protein Kinase That Negatively Regulates Cytokine Signaling

    Daniela Ungureanu;Jinhua Wu;Jinhua Wu;Tuija Pekkala;Yashavanthi Niranjan

  • Autoinhibition of Jak2 tyrosine kinase is dependent on specific regions in its pseudokinase domain.

    Pipsa Saharinen;Mauno Vihinen;Olli Silvennoinen

  • A robust methodology to subclassify pseudokinases based on their nucleotide-binding properties.

    James M. Murphy;James M. Murphy;Qingwei Zhang;Samuel N. Young;Michael L. Reese

  • Crystal structures of the JAK2 pseudokinase domain and the pathogenic mutant V617F

    Rajintha M Bandaranayake;Daniela Ungureanu;Yibing Shan;David E Shaw;David E Shaw

  • ARIP3 (Androgen Receptor-Interacting Protein 3) and Other PIAS (Protein Inhibitor of Activated STAT) Proteins Differ in Their Ability to Modulate Steroid Receptor-Dependent Transcriptional Activation

    Noora Kotaja;Saara Aittomäki;Olli Silvennoinen;Jorma J. Palvimo

  • Tudor staphylococcal nuclease is an evolutionarily conserved component of the programmed cell death degradome.

    Jens F. Sundström;Alena Vaculova;Andrei P. Smertenko;Eugene I. Savenkov

Frequent Co-Authors

Stevan R. Hubbard
Stevan R. Hubbard New York University
Mika Rämet
Mika Rämet Oulu University Hospital
James N. Ihle
James N. Ihle St. Jude Children's Research Hospital
Xi Yang
Xi Yang University of Manitoba
Jorma J. Palvimo
Jorma J. Palvimo University of Eastern Finland
David E. Shaw
David E. Shaw D. E. Shaw Research
James M. Murphy
James M. Murphy Walter and Eliza Hall Institute of Medical Research
John J. O'Shea
John J. O'Shea National Institutes of Health
Jeffrey J. Babon
Jeffrey J. Babon Walter and Eliza Hall Institute of Medical Research
M. Celeste Simon
M. Celeste Simon University of Pennsylvania

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Exploring Molecular Biology opens doors to a variety of scientific and healthcare fields. Many students consider online degrees for flexibility and cost savings. For related interests, an online Master of Library and Information Science is a popular choice, but students should carefully weigh the cost of mlis degree us to find affordable options.

For those interested in healthcare and communications, speech-language pathology (SLP) is another rewarding path. There are asha certified slp programs available online that can lead to licensure and a meaningful career helping others. If your background is not in communication sciences, an slp bridge program online can let you transition into this field with bridge courses.

For non-nursing graduates, moving into nursing is also possible. Consider an non nursing degree to bsn online option to fast-track your entry into healthcare practice.

Best Scientists Citing Olli Silvennoinen

Trending Scientists

Recently Published Articles